Market Research Logo

Melanoma Diagnostic Tests - Medical Devices Pipeline Assessment, 2017

Melanoma Diagnostic Tests - Medical Devices Pipeline Assessment, 2017

Summary

GlobalData's Medical Devices sector report, “Melanoma Diagnostic Tests - Medical Devices Pipeline Assessment, 2017 provides an overview of Melanoma Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Melanoma Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.Scope

  • Extensive coverage of the Melanoma Diagnostic Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Melanoma Diagnostic Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Melanoma Diagnostic Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date


  • Introduction
    • Melanoma Diagnostic Tests Overview
  • Products under Development
    • Melanoma Diagnostic Tests - Pipeline Products by Stage of under Development
      • Table Figure 1: Melanoma Diagnostic Tests - Pipeline Products by Stage of under Development
      • Table Melanoma Diagnostic Tests - Pipeline Products by Stage of under Development
    • Melanoma Diagnostic Tests - Pipeline Products by Territory
      • Table Figure 2: Melanoma Diagnostic Tests - Pipeline Products by Territory
      • Table Melanoma Diagnostic Tests - Pipeline Products by Territory
    • Melanoma Diagnostic Tests - Pipeline Products by Regulatory Path
      • Table Figure 3: Melanoma Diagnostic Tests - Pipeline Products by Regulatory Path
      • Table Melanoma Diagnostic Tests - Pipeline Products by Regulatory Path
    • Melanoma Diagnostic Tests - Pipeline Products by Estimated Approval Date
      • Table Figure 4: Melanoma Diagnostic Tests - Pipeline Products by Estimated Approval Date
      • Table Melanoma Diagnostic Tests - Pipeline Products by Estimated Approval Date
    • Melanoma Diagnostic Tests - Ongoing Clinical Trials
      • Table Figure 5: Melanoma Diagnostic Tests - Ongoing Clinical Trials
      • Table Melanoma Diagnostic Tests - Ongoing Clinical Trials
  • Melanoma Diagnostic Tests - Pipeline Products under Development by Companies
    • Melanoma Diagnostic Tests Companies - Pipeline Products by Stage of Development
      • Table Melanoma Diagnostic Tests Companies - Pipeline Products by Stage of Development
    • Melanoma Diagnostic Tests - Pipeline Products by Stage of Development
      • Table Melanoma Diagnostic Tests - Pipeline Products by Stage of Development
  • Melanoma Diagnostic Tests Companies and Product Overview
    • Abbott Diagnostics Company Overview
      • Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
        • Table Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
        • Table MAGE-A3 Companion Diagnostic Assay - Melanoma - Product Status
        • Table MAGE-A3 Companion Diagnostic Assay - Melanoma - Product Description
    • Adaptive Biotechnologies Corp Company Overview
      • Adaptive Biotechnologies Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table Adaptive Biotechnologies Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table Companion Diagnostic Test - Melanoma Cancer - Product Status
        • Table Companion Diagnostic Test - Melanoma Cancer - Product Description
    • Agilent Technologies Inc Company Overview
      • Agilent Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Agilent Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table MK-3475 Companion Diagnostic Test - Product Status
        • Table MK-3475 Companion Diagnostic Test - Product Description
    • BioMark Diagnostics Inc. Company Overview
      • BioMark Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table BioMark Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Metabolomics-Based Diagnostic Assay - Melanoma - Product Status
        • Table Metabolomics-Based Diagnostic Assay - Melanoma - Product Description
    • BioMarker Strategies LLC Company Overview
      • BioMarker Strategies LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table BioMarker Strategies LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table Ex Vivo Biomarker Test - Melanoma - Product Status
        • Table Ex Vivo Biomarker Test - Melanoma - Product Description
        • Table PathMAP - Product Status
        • Table PathMAP - Product Description
    • Biosceptre International Ltd Company Overview
      • Biosceptre International Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Biosceptre International Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Skin Cancer IHC Diagnostic Test - Product Status
        • Table Skin Cancer IHC Diagnostic Test - Product Description
    • Ceres Nanosciences Inc Company Overview
      • Ceres Nanosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Ceres Nanosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Melanoma Skin Patch Sweat Test - Product Status
        • Table Melanoma Skin Patch Sweat Test - Product Description
    • Dana-Farber Cancer Institute Inc Company Overview
      • Dana-Farber Cancer Institute Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Dana-Farber Cancer Institute Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Biomarker Test For Immune Checkpoint Inhibitor Therapy - Product Status
        • Table Biomarker Test For Immune Checkpoint Inhibitor Therapy - Product Description
    • Digna Biotech SL Company Overview
      • Digna Biotech SL Pipeline Products & Ongoing Clinical Trials Overview
        • Table Digna Biotech SL Pipeline Products & Ongoing Clinical Trials Overview
        • Table Melanoma Test - Product Status
        • Table Melanoma Test - Product Description
    • Exosomics Siena SpA Company Overview
      • Exosomics Siena SpA Pipeline Products & Ongoing Clinical Trials Overview
        • Table Exosomics Siena SpA Pipeline Products & Ongoing Clinical Trials Overview
        • Table ExoTEST Melanoma - Product Status
        • Table ExoTEST Melanoma - Product Description
    • Genomic Health Inc Company Overview
      • Genomic Health Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Genomic Health Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Prognostic Test - Melanoma - Product Status
        • Table Prognostic Test - Melanoma - Product Description
    • Hospital Universitario Cruces Company Overview
      • Hospital Universitario Cruces Pipeline Products & Ongoing Clinical Trials Overview
        • Table Hospital Universitario Cruces Pipeline Products & Ongoing Clinical Trials Overview
        • Table Hospital Universitario Cruces Diagnostic Assay - Melanoma - Product Status
        • Table Hospital Universitario Cruces Diagnostic Assay - Melanoma - Product Description
    • Hummingbird Diagnostics GmbH Company Overview
      • Hummingbird Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview
        • Table Hummingbird Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview
        • Table Hummingbird Diagnostics GmbH Diagnostic Test - Melanoma - Product Status
        • Table Hummingbird Diagnostics GmbH Diagnostic Test - Melanoma - Product Description
    • ImmunID SAS Company Overview
      • ImmunID SAS Pipeline Products & Ongoing Clinical Trials Overview
        • Table ImmunID SAS Pipeline Products & Ongoing Clinical Trials Overview
        • Table ImmunTraCkeR - Metastatic Melanoma - Product Status
        • Table ImmunTraCkeR - Metastatic Melanoma - Product Description
        • Table ImmunID SAS - Ongoing Clinical Trials Overview
        • Table ImmunTraCkeR - Metastatic Melanoma - Multicenter Clinical Study to Assess the Use of Immune
        • Table ImmunTraCkeR - Metastatic Melanoma - Validation of ImmunTraCkeR in Metastatic Melanoma
    • Institut Pasteur Company Overview
      • Institut Pasteur Pipeline Products & Ongoing Clinical Trials Overview
        • Table Institut Pasteur Pipeline Products & Ongoing Clinical Trials Overview
        • Table Institut Pasteur Diagnostic Test - Melanoma - Product Status
        • Table Institut Pasteur Diagnostic Test - Melanoma - Product Description
    • InterGenetics Inc Company Overview
      • InterGenetics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table InterGenetics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table OncoVue Skin - Product Status
        • Table OncoVue Skin - Product Description
    • IV Diagnostics Inc Company Overview
      • IV Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table IV Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table IVDiagnostics Diagnostic Test - Melanoma - Product Status
        • Table IVDiagnostics Diagnostic Test - Melanoma - Product Description
    • John Hopkins University Company Overview
      • John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview
        • Table John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview
        • Table Biomarker Based Diagnostic Assay - Melanoma - Product Status
        • Table Biomarker Based Diagnostic Assay - Melanoma - Product Description
    • Louisville Bioscience, Inc. Company Overview
      • Louisville Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Louisville Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Melanoma Remission pT Test - Product Status
        • Table Melanoma Remission pT Test - Product Description
    • MDNA Life Sciences Inc Company Overview
      • MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table MDNA Life Sciences Inc Diagnostic Test - Melanoma - Product Status
        • Table MDNA Life Sciences Inc Diagnostic Test - Melanoma - Product Description
    • Melanovus Oncology Inc Company Overview
      • Melanovus Oncology Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Melanovus Oncology Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Companion Diagnostic Test - Melanoma - Product Status
        • Table Companion Diagnostic Test - Melanoma - Product Description
    • Memorial Sloan Kettering Cancer Center Company Overview
      • Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview
        • Table Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview
        • Table Melanoma Biomarker - Resistance to RAF Inhibitors - Product Status
        • Table Melanoma Biomarker - Resistance to RAF Inhibitors - Product Description
    • MyCardio LLC Company Overview
      • MyCardio LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table MyCardio LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table MyCardio LLC Diagnostic Assay - Melanoma - Product Status
        • Table MyCardio LLC Diagnostic Assay - Melanoma - Product Description
    • Orion Genomics LLC Company Overview
      • Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table Diagnostic Assay - Melanoma - Product Status
        • Table Diagnostic Assay - Melanoma - Product Description
    • Oryzon Genomics SA Company Overview
      • Oryzon Genomics SA Pipeline Products & Ongoing Clinical Trials Overview
        • Table Oryzon Genomics SA Pipeline Products & Ongoing Clinical Trials Overview
        • Table Diagnostic Assay - Melanoma Cancer - Product Status
        • Table Diagnostic Assay - Melanoma Cancer - Product Description
        • Table Prognostic Assay - Melanoma Cancer - Product Status
        • Table Prognostic Assay - Melanoma Cancer - Product Description
    • Pacific Edge Ltd Company Overview
      • Pacific Edge Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Pacific Edge Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Prognostic Assay - Melanoma - Product Status
        • Table Prognostic Assay - Melanoma - Product Description
    • Protea Biosciences Group Inc Company Overview
      • Protea Biosciences Group Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Protea Biosciences Group Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Mass Spectrometry Imaging Based Test - Malignant Melanoma - Product Status
        • Table Mass Spectrometry Imaging Based Test - Malignant Melanoma - Product Description
        • Table Protea Biosciences Group Inc - Ongoing Clinical Trials Overview
        • Table Mass Spectrometry Imaging Based Test - Malignant Melanoma - Clinical Research Study for New Molecular Imaging Test for the Differential Diagnosis of Malignant Melanoma
    • Qiagen NV Company Overview
      • Qiagen NV Pipeline Products & Ongoing Clinical Trials Overview
        • Table Qiagen NV Pipeline Products & Ongoing Clinical Trials Overview
        • Table Companion Diagnostic Test - Binimetinib - Product Status
        • Table Companion Diagnostic Test - Binimetinib - Product Description
        • Table QIAsymphony - NRAS Assay - Product Status
        • Table QIAsymphony - NRAS Assay - Product Description
    • Roche Diagnostics International Ltd Company Overview
      • Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Cobimetinib Companion Diagnostic Assay - Product Status
        • Table Cobimetinib Companion Diagnostic Assay - Product Description
        • Table Companion Diagnostic Test - MEK 0973 - Product Status
        • Table Companion Diagnostic Test - MEK 0973 - Product Description
        • Table ETBR ADC Companion Diagnostic Test - Product Status
        • Table ETBR ADC Companion Diagnostic Test - Product Description
        • Table PDL1+Zelboraf Companion Diagnostic Test - Product Status
        • Table PDL1+Zelboraf Companion Diagnostic Test - Product Description
        • Table Zelboraf Companion Diagnostic Test - Metastatic Melanoma - Product Status
        • Table Zelboraf Companion Diagnostic Test - Metastatic Melanoma - Product Description
    • Rosetta Genomics Ltd Company Overview
      • Rosetta Genomics Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Rosetta Genomics Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table microRNA-Based Diagnostic Test - Melanoma - Product Status
        • Table microRNA-Based Diagnostic Test - Melanoma - Product Description
    • Sividon Diagnostics GmbH Company Overview
      • Sividon Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview
        • Table Sividon Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview
        • Table Sividon Diagnostics GmbH Diagnostic Assay - Melanoma - Product Status
        • Table Sividon Diagnostics GmbH Diagnostic Assay - Melanoma - Product Description
    • SomaLogic Inc Company Overview
      • SomaLogic Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table SomaLogic Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table SOMAscan Assay - Melanoma - Product Status
        • Table SOMAscan Assay - Melanoma - Product Description
    • Treos Bio Inc Company Overview
      • Treos Bio Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Treos Bio Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table PolyPEPI 613 CDx - Product Status
        • Table PolyPEPI 613 CDx - Product Description
    • University of California San Francisco Company Overview
      • University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview
        • Table University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview
        • Table Diagnostic Assay - Uveal Melanoma - Product Status
        • Table Diagnostic Assay - Uveal Melanoma - Product Description
    • University of Louisville Company Overview
      • University of Louisville Pipeline Products & Ongoing Clinical Trials Overview
        • Table University of Louisville Pipeline Products & Ongoing Clinical Trials Overview
        • Table Melanoma Sentinel Lymph Node Biomarker Test - Product Status
        • Table Melanoma Sentinel Lymph Node Biomarker Test - Product Description
    • University of Maryland Baltimore Company Overview
      • University of Maryland Baltimore Pipeline Products & Ongoing Clinical Trials Overview
        • Table University of Maryland Baltimore Pipeline Products & Ongoing Clinical Trials Overview
        • Table Prognostic Biomarker Test - Melanoma - Product Status
        • Table Prognostic Biomarker Test - Melanoma - Product Description
    • Vanderbilt University Company Overview
      • Vanderbilt University Pipeline Products & Ongoing Clinical Trials Overview
        • Table Vanderbilt University Pipeline Products & Ongoing Clinical Trials Overview
        • Table Companion Diagnostic Assay - Melanoma - Product Status
        • Table Companion Diagnostic Assay - Melanoma - Product Description
    • Zymera, Inc Company Overview
      • Zymera, Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Zymera, Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Prognostic Assay - Melanoma - Product Status
        • Table Prognostic Assay - Melanoma - Product Description
  • Melanoma Diagnostic Tests - Recent Developments
    • Sep 05, 2017: Rosetta Genomics to Reduce Operating and Other Expenses
    • Aug 31, 2017: BioMarker Strategies Announces Two New Patents Granted in Japan, For the Company's Core Diagnostics Technology PathMAP
    • Aug 30, 2017: bioMerieux – First-Half 2017 Results
    • Aug 30, 2017: GSK responds to UK Life Sciences Industrial Strategy
    • Aug 22, 2017: Protea Expands Clinical Study for New Melanoma Test
    • Aug 15, 2017: Agilent Technologies Reports Third-Quarter Fiscal Year 2017 Financial Results
    • Aug 08, 2017: HTG Molecular Diagnostics Reports Second Quarter 2017 Results
    • Aug 01, 2017: Genomic Health Announces Second Quarter 2017 Financial Results and Reports Recent Business Progress
    • Jul 31, 2017: AtCor Signs New Agreement Major entry point into New York health systems market
    • Jul 28, 2017: ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2017
    • Jul 27, 2017: Adaptive Biotechnologies Expands Leadership to Bolster Integration of Immune Profiling into Clinical Care Setting
    • Jul 27, 2017: QIAGEN Reports Results for Second Quarter and First Half of 2017
    • Jul 26, 2017: GSK delivers further progress in Q2 and sets out new priorities for the Group
    • Jul 25, 2017: Karenann Terrell appointed Chief Digital & Technology Officer, GSK
    • Jul 25, 2017: Quest Diagnostics Reports Second Quarter 2017 Financial Results, Raises 2017 Financial Outlook
    • Jul 21, 2017: GSK announces Board and Committee changes
    • Jul 20, 2017: bioMerieux – Second-Quarter 2017 Business Review
    • Jul 20, 2017: Professor John Spencer's Lab to Carry Out Vital Skin Cancer Research Thanks to New Grant
    • Jul 18, 2017: Hans E. Bishop to Join Agilent's Board of Directors
    • Jul 06, 2017: Rosetta Genomics Expands Patent Portfolio in Canada, United States, and China
    • Jun 19, 2017: GSK confirms start date for Luke Miels
    • Jun 15, 2017: Oxford Immunotec Announces Favorable Claim Construction Ruling in Patent Infringement Litigation
    • Jun 01, 2017: MolecularMD achieves status as an ArcherDX Certified Service Provider and expands offering of novel NGS chemistries
    • May 22, 2017: Agilent Technologies Reports Second-Quarter Fiscal Year 2017 Financial Results
    • May 16, 2017: Oryzon announces appointment of new Chief Medical Officer and expansion of its Medical Department
    • May 15, 2017: HTG Molecular Diagnostics Reports First Quarter 2017 Results
    • May 09, 2017: ORYZON Reports Financial Results and Corporate Update for the 1st Quarter, 2017
    • May 09, 2017: Genomic Health Announces First Quarter 2017 Financial Results and Reports Recent Business Progress
    • May 04, 2017: Agilent Technologies Receives Multiple Awards at Scientific Conference in China
    • May 02, 2017: QIAGEN reports results for first quarter 2017
    • May 02, 2017: Myriad Genetics Reports Fiscal Third-Quarter 2017 Financial Results
    • May 01, 2017: Rosetta Genomics Expands Patent Portfolio in Europe and Japan
    • Apr 26, 2017: GSK delivers another quarter of continued progress
    • Apr 20, 2017: Quest Diagnostics Reports First Quarter 2017 Financial Results, Raises 2017 Financial Outlook
    • Apr 20, 2017: bioMerieux – First-Quarter 2017 Business Review
    • Apr 18, 2017: Protea Announces 2016 Year End Results
    • Apr 05, 2017: SomaLogic announces the appointment of long-time Board member as Chief Executive Officer
    • Apr 04, 2017: GSK responds to Cyclone Debbie
    • Mar 30, 2017: Rosetta Genomics Reports 2016 Fourth Quarter and Full Year Financial Results
    • Mar 23, 2017: HTG Molecular Diagnostics Reports Fourth Quarter and Full Year 2016 Results
    • Mar 20, 2017: Agilent Technologies Hires Samraat "Sam" Raha to Head Strategy and Corporate Development
    • Mar 15, 2017: Agilent Technologies Board of Directors Elects Koh Boon Hwee as New Chairman
    • Mar 14, 2017: Agilent Technologies Receives 2017 Scientists' Choice Award for Best Webinar Series
    • Mar 07, 2017: HTG Molecular Diagnostics Appoints New Chair of the Board of Directors
    • Mar 01, 2017: bioMerieux – 2016 Financial Results
    • Feb 24, 2017: ORYZON Reports Financial Results and Corporate Update for the Fourth Quarter and Year Ended December 31, 2016
    • Feb 21, 2017: Agilent Technologies Receives Dow's Western Canada Science and Technical Excellence Conference Awards (WesTEC) for Technical Excellence and
    • Feb 16, 2017: GSK and EMBL have signed an agreement to enhance understanding of disease and drug mechanisms
    • Feb 14, 2017: Agilent Technologies Reports First-Quarter 2017 Results
    • Feb 14, 2017: Genomic Health Announces 2016 Fourth Quarter and Year-End Financial Results, Provides 2017 Financial Outlook
    • Feb 08, 2017: GlaxoSmithKline: Results announcement for the fourth quarter 2016
    • Feb 07, 2017: Myriad Genetics Reports Fiscal Second-Quarter 2017 Financial Results
    • Feb 01, 2017: QIAGEN Reports Results for Fourth Quarter and Full-year 2016
    • Jan 26, 2017: Quest Diagnostics Reports Fourth Quarter And Full Year 2016 Financial Results; Provides Guidance For Full Year 2017
    • Jan 26, 2017: Quest Diagnostics Partners With Montefiore Health System to Deliver High-Value, Innovative Laboratory Services
    • Jan 19, 2017: bioMerieux – Fourth-Quarter 2016 Business Review
    • Jan 19, 2017: Abbas Hussain to leave GSK
    • Jan 19, 2017: Luke Miels appointed President, Global Pharmaceuticals, GSK
    • Dec 21, 2016: Agilent Technologies Receives Top Innovation Award from The Analytical Scientist
    • Dec 19, 2016: GSK announces Board changes
    • Dec 15, 2016: Quest Diagnostics Board of Directors Elects Stephen H. Rusckowski Chairman of the Board
    • Nov 24, 2016: Pacific Edge Interim Results to 30 September 2016
    • Nov 22, 2016: Protea Announces Third Quarter 2016 Results
    • Nov 15, 2016: Agilent Technologies Reports Fourth-Quarter 2016 Results
    • Nov 14, 2016: HTG Molecular Diagnostics Reports Third Quarter 2016 Results
    • Nov 11, 2016: Quest Diagnostics Raises Revenue Growth Outlook, Increases Dividend at 2016 Investor Day
    • Nov 10, 2016: Protea Appoints David Halverson As President
    • Nov 07, 2016: Pierre Boulud appointed Corporate Vice Presidentof the Asia Pacific region at bioMerieux
    • Nov 02, 2016: QIAGEN Reports Results for Third Quarter and First Nine Months of 2016
    • Nov 02, 2016: QIAGEN launches restructuring initiatives, revises outlook for 2016 earnings and provides initial net sales and adjusted earnings guidance for 2017
    • Nov 01, 2016: Genomic Health Reports Third Consecutive Quarter of Double-Digit Revenue Growth in Announcement of Third Quarter 2016 Financial Results
    • Nov 01, 2016: Myriad Genetics Reports Fiscal First-Quarter 2017 Financial Results
    • Oct 26, 2016: GlaxoSmithKline: Results Announcement for the third quarter 2016
    • Oct 24, 2016: ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2016
    • Oct 20, 2016: bioMerieux-Business Review for the nine months ended September 30,2016
    • Oct 20, 2016: Quest Diagnostics Reports Third Quarter 2016 Financial Results
    • Oct 20, 2016: Rosetta Genomics Appoints Mark R. Willig as Chief Commercial Officer
    • Sep 29, 2016: GlaxoSmithKline appoints Brian McNamara as CEO of GSK Consumer Healthcare
    • Sep 29, 2016: Myriad Appoints Chip Parkinson as EVP for Reimbursement Strategy
    • Sep 26, 2016: Rosetta Genomics Reports 2016 Second Quarter Financial Results
  • Appendix
    • Methodology
      • Table Glossary
    • About GlobalData
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report